JACKSONVILLE, Fla., July 23, 2008 (PRIME NEWSWIRE) -- BodyTel Scientific Inc. (OTCBB:BDYT), a developer and manufacturer of wireless telemedical systems, announces today that the GlucoTel system has received certification from the Netherlands Organization for Applied Scientific Research TNO ("TNO") by passing rigorous quality assurance tests. TNO is an independent group founded in 1932 that, among other things, thoroughly tests and inspects medical devices.
"The TNO approval offers consumers the reassurance that a product has been thoroughly tested and periodically monitored by an independent organization. TNO is known throughout Europe for their high standards and its tests are often more rigorous than the requirements for CE Marking," stated, BodyTel CEO, Stefan Schraps. "Receiving the TNO approval is a testament to the accuracy and quality of the GlucoTel system."
Dion van de Ven, CEO of TeleHealth Services, BodyTel's distributor in the Benelux region, commented, "The TNO approval seal will assist us with the introduction of this telemedical solution within medical institutes, as well as assist our efforts in differentiating our product from our competitors. Also, there are already some insurance companies who are considering requiring the TNO certificate in order to have the costs reimbursed by them. Most important for the Benelux market is that the certification gives the quality-image that GlucoTel deserves."
The GlucoTel system is a complete telemedical blood glucose monitoring and diabetes management system, supporting patients and healthcare professionals in the treatment and control of diabetes and other associated disorders. GlucoTel electronically measures the blood sugar level and then sends it automatically via Bluetooth to the patient's cell phone. Measured values are automatically transmitted from the cell phone to BodyTel's online database via mobile Internet connection and stored on a long-term basis in the patient's secured profile. To facilitate better diabetes management, the patient and any authorized persons, e.g. healthcare professionals or other caregivers, can access the database 'BodyTel Center' at www.bodytel.com via the Internet at any time using a secure login.
The GlucoTel system is the first system of its kind that can provide real-time monitoring and management through its optional alarm functions. If defined by the caregiver, the BodyTel Center can create an alert message that can be sent to caregivers such as parents of a diabetic child, thereby informing them immediately of a potential out-of-range result or other unusual behavior like not performing any test within a predefined time frame. The versatility of the system provides all these tools, but use is completely optional and can be enabled or disabled based on patient, caregivers or healthcare professionals' requirements preventing possible serious complications if action is taken without delay.
About BodyTel
BodyTel is a German-American telehealth company that specializes in telemedical monitoring and management systems for chronic diseases. The company combines its know-how in telecommunications, Internet and medical technology/diagnostics to create new products and services for the changing needs of global health. BodyTel products are designed not only to simplify home monitoring by patients, but also to ease the communication of 'measured body values' to healthcare professionals or other caregivers by bridging the gap between the patient and the caregivers instantaneously and in real-time. BodyTel's products -- GlucoTel, PressureTel and WeightTel -- are each at different stages of development and approval processes.
Further information can be found at www.bodytel.com.
Forward-Looking Statements
Statements in this news release that are not historical are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur. Forward-looking statements in this news release include: The TNO approval seal will assist us with the introduction of this telemedical solution within medical institutes, as well as assist our efforts in differentiating our product from our competitors. It is important to note that the Company's actual outcomes may differ materially from those statements contained in this press release. Factors which may delay or prevent these forward looking statements from being realized include, but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones or other risk factors and matters set forth in the Company's Annual Report on Form 10-KSB for the year ended February 28, 2007 and the Company's periodic reports filed with the SEC. These reports are available on our investor relations website at www.bodytel.com and on the SEC's website at http://www.sec.gov. BodyTel undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.